HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.

Abstract
The efficacy of alfa-interferon (alfa-IFN) in essential thrombocythemia (ET) patients has been reported by several authors. The aim of this study is to assess the magnitude of the effect of alfa-IFN on the neoplastic clone. As of December 1993, 11 ET patients received alfa-IFN at a dose of 3-6 MU/s.c./day for 6 months. Ten of 11 obtained complete hematological remission (CHR) and one achieved partial hematological remission. Megakaryocyte concentration was reduced in six cases. The spleen,which was enlarged in four patients, decreased in size in two patients. Seven of eight patients who were symptomatic at diagnosis obtained resolution of symptoms. In order to obtain indications about the structural modifications induced by alfa-IFN in ET megakaryocytes (Mks), Fourier-transform infra-red microspectroscopy analysis performed on 10 single Mks of each patient, was done in seven of 11 patients; the analysis showed a reduction of A1/A2 ratios (A1 integrated area of the band at 1080 cm(-1) due to the nucleic acids absorption; A2 integrated area of the band at 1540 cm(-1) due to proteic components absorption) in five cases, and in three of these five patients A1/A2 ratios achieved normal values. After alfa-IFN treatment we did not observe any change in the methylation pattern of DNA from the granulocyte fraction. Our results confirm the efficacy of alfa-IFN in ET patients, and the decrease of A1/A2 ratios in several patients is a demonstration of the depth of the effect of alfa-IFN on the neoplastic clone. The results of clonality studies showed the persistence of clonal hematopoiesis. Whether higher alfa-IFN dose and/or more prolonged alfa-IFN therapy may allow a restoration of polyclonal hematopoiesis remains to be determined and should be explored in future clinical trials.
AuthorsS Sacchi, L Gugliotta, F Papineschi, A M Liberati, S Rupoli, C Delfini, M Ruggeri, L Cavanna, A Bucalossi, E Benedetti, C Ferrandina, G Vinci, M Morselli, G Torelli
JournalLeukemia (Leukemia) Vol. 12 Issue 3 Pg. 289-94 (Mar 1998) ISSN: 0887-6924 [Print] England
PMID9529121 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Interferon-alpha
  • DNA
  • Phosphoglycerate Kinase
Topics
  • Adolescent
  • Adult
  • Analysis of Variance
  • DNA (blood)
  • Hematopoiesis
  • Hematopoietic Stem Cells (pathology)
  • Heterozygote
  • Humans
  • Interferon-alpha (adverse effects, therapeutic use)
  • Leukocyte Count
  • Megakaryocytes (drug effects, pathology)
  • Middle Aged
  • Phosphoglycerate Kinase (genetics)
  • Platelet Count
  • Polymorphism, Restriction Fragment Length
  • Splenomegaly (therapy)
  • Thrombocytosis (blood, therapy)
  • X Chromosome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: